PDF(1170 KB)
PDF(1170 KB)
PDF(1170 KB)
宁夏地区160046名新生儿先天性肾上腺皮质增生症筛查与治疗随访分析
Screening and follow-up treatment of 160 046 neonates with congenital adrenal hyperplasia in Ningxia, China
目的 了解宁夏地区新生儿先天性肾上腺皮质增生症 （CAH） 的发病率和随访治疗情况。方法 对宁夏地区所有助产机构 （136家） 2014年7月至2016年3月出生的160046名新生儿进行CAH筛查的资料进行分析总结。结果 160046名接受CAH筛查的新生儿中，筛查阳性70例 （0.044%）；确诊CAH 11例，CAH发病率为1/14550 （0.069‰），其中失盐型9例 （死亡2例），单纯男性化2例。9例患儿一经确诊，立即给予糖皮质激素治疗，患儿生长发育良好。结论 宁夏地区新生儿CAH发病率为1/14550；在宁夏地区开展CAH筛查是非常必要的，对确诊患儿给予积极治疗可改善预后。
Objective To investigate the incidence of congenital adrenal hyperplasia (CAH) and treatment outcomes in neonates in Ningxia, China. Methods The clinical data of CAH screening for 160 046 neonates who were born in midwifery institutions in Ningxia from July 2014 to March 2016 were analyzed. Results Among the 160 046 neonates who underwent CAH screening, 70 (0.044%) obtained a positive result and 11 were diagnosed with CAH; the incidence rate of CAH was 1/14 550 (0.069‰). Among the 11 neonates diagnosed with CAH, 9 had the salt wasting type (2 died) and 2 had simple virilization. The 9 neonates were given glucocorticoids immediately once diagnosed and all of them achieved good growth and development. Conclusions The incidence of neonatal CAH in Ningxia is 1/14 550. It is very necessary to carry out CAH screening in Ningxia, and active treatment can improve the prognosis of neonates with CAH.
先天性肾上腺皮质增生症 / 17-羟孕酮 / 新生儿
Congenital adrenal hyperplasia / 17-Hydroxyprogesterone / Neonate
[1] Forest MG.Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency[J].Hum Reprod Update,2004,10(6):469-485.
[2] 毛新梅,马晓燕,李宏艳,等.宁夏回族自治区新生儿疾病筛查现状调查[J].中国妇幼保健,2012,27(36):5988-5990.
[3] 毛新梅,井淼,李晓强,等.2010-2014年宁夏新生儿先天性甲状腺功能减低症和苯丙酮尿症筛查分析[J].宁夏医科大学学报,2015,37(8):934-937.
[4] 毛维玉,郭辉,闵娟,等.早产新生儿体重对CAH筛查中17-羟孕酮结果的影响分析[J].国际医药卫生导报,2008,14(7):11-14.
[5] 杜敏联.21-羟化酶缺乏症[M]//顾学范.临床遗传代谢病.北京:人民卫生出版社,2015:296-303.
[6] 罗小平,祝捷.先天性肾上腺皮质增生症的诊断及治疗[J].实用儿科临床杂志,2006,21(8):510-512.
[7] 曹敏.先天性肾上腺皮质增生症的若干临床问题[J].浙江临床医学,2006,8(7):673-674.
[8] 田国力,朱伟明,王燕敏,等.新生儿先天性肾上腺皮质增生症筛查的初步报告[J].检验医学,2010,25(2):86-88.
[9] 袁佩,许国锋,王秋伟,等.常州地区2001-2010年新生儿先天性肾上腺皮质增生症筛查结果分析[J].中国全科医学,2012,15(12):4249-4251.
[10] 罗超,范歆,林彩娟,等.广西地区单胎和双胎新生儿先天性肾上腺皮质功能增生症筛查确诊结果分析[J].中国儿童保健杂志,2016,24(2):183-184.
[11] 徐小兰,魏静,黄志华,等.南昌地区新生儿肾上腺皮质增生症的筛查结果分析[J].中国优生与遗传杂志,2014,22(2):87-88.
[12] 田丽萍,卜晓萍.济南地区新生儿先天性肾上腺皮质增生症的筛查分析[J].中国妇幼保健,2012,27(11):1666-1668.
[13] 张李霞,苏晞.佛山市新生儿先天性肾上腺皮质增生症筛查结果分析[J].中国妇幼保健,2013,28(8):1292-1294.
[14] 王本敬,陈亚平,陈瑛.2010年-2012年苏州地区新生儿先天性肾上腺皮质增生症筛查结果分析[J].中国优生与遗传杂志,2013,21(10):80-83.
[15] Falhammar H,Frisén L,Norrby C,et al.Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency[J].J Clin Endocrinol Metab,2014,99(12):E2715-E2721.
[16] Nascimento ML,Cristiano AN,Campos TD,et al.Ten-year evaluation of a Neonatal Screening Program for congenital adrenal hyperplasia[J].Arq Bras Endocrinol Metabol,2014,58(7):765-771.
[17] Tajima T,Fujieda K,Nakae J,et al.Molecular basis of nonclassical steroid 21-hydroxylase deficiency detected by neonatal mass screening in Japan[J].J Clin Endocrinol Metab,1997,82(7):2350-2356.
[18] Larsson A,Hagenfeldt L,von Döbeln U,et al.Neonatal screening for congenital adrenal hyperplasia using 17-hydroxyprogesterone assay in filter paper blood spots[J].Hom Res,1988,30(6):235-240.
[19] Therrell BL Jr,Berenbaum SA,Manter-Kapanke V,et al.Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia[J].Pediatrics,1998,101(4 Pt 1):583-590.
[20] Gleeson HK,Wiley V,Wilcken B,et al.Two-year pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia[J].J Paediatr Child Health,2008,44(10):554-559.
[21] Gruñieiro-Papendieck L,Chiesa A,Mendez V,et al.Neonatal screening for congenital adrenal hyperplasia:experience and results in Argentina[J].J Pediatr Endocrinol Metab,2008,21(1):73-78.
[22] 叶军.先天性肾上腺皮质增生症[M]//顾学范,叶军.新生儿疾病筛查.上海:上海科技文献出版社,2003:185-197.
宁夏卫生计生委重点科研计划项目[NW2015-054]。
